

# **2024-2029 Cancer Diagnostic Testing: A Market on the Verge of Explosion--US, Europe, Japan--Supplier Shares and Market Segment Forecasts by Test--Technological Breakthroughs, Emerging Tests, Competitive Analysis**

<https://marketpublishers.com/r/244F78DE9D2DEN.html>

Date: November 2024

Pages: 0

Price: US\$ 14,500.00 (Single User License)

ID: 244F78DE9D2DEN

## **Abstracts**

LeadingMarketResearch's new report is a study of the major business opportunities emerging in the global cancer diagnostics market during the next five years. The report examines trends in the U.S., Europe and Japan; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers. The report is available by section, and can be customized to specific information needs and budget.

### **Rationale**

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

### **Geographic Coverage**

France, Germany, Italy, Japan, Spain, UK, USA

### **Worldwide Market Overview**

Five-year test volume and sales projections by country.

Comprehensive market segmentation analysis, including review

of the market dynamics, structure, size, growth and major suppliers by country.

Estimated universe of laboratories performing cancer diagnostic testing by country.

Cancer statistics, etiology and recent developments in the U.S., Europe, and Japan.

Business Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Over 200 Current and Emerging Cancer Diagnostic Test

Biochemical Markers

- Oncogenes
- Growth Factors
- Hormones
- Colony Stimulating Factors
- Lymphokines
- Immunohistochemical Stains, and others.

ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.

Supplier Shares, Sales and Volume Forecasts

Sales and market shares of major cancer diagnostic product suppliers by individual test and country.

Five-year test volume and sales forecasts for major tumor markers by country and market segment, including:

Hospitals

- Commercial/Private Laboratories
- Physician Offices/Group Practices
- Cancer Clinics
- Ambulatory Care Centers

Instrumentation Review

Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.

Technology Assessment

Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing.

Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.

Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.

#### Competitive Strategies

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

## Contents

- I. Introduction
- II. Worldwide Market Overview

### **1. MARKET OVERVIEW**

### **2. WORLDWIDE MARKET STRUCTURE**

### **3. WORLDWIDE MARKET SIZE AND GROWTH**

#### III. Major Product Development Opportunities

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- D. Auxiliary Products

#### IV. Design Criteria for Decentralized Testing Products

#### V. Alternative Market Penetration Strategies

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies

### **1. MARKETING APPROACHES**

### **2. PRODUCT COMPLEXITY**

### **3. CUSTOMER PREFERENCE**

### **4. ESTABLISHED SUPPLIERS**

### **5. EMERGING SUPPLIERS**

### **6. MAJOR TYPES OF DISTRIBUTORS**

### **7. MARKET SEGMENTATION FACTOR**

#### VI. Potential Market Entry Barriers and Risks

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges
- VII. Worldwide Market and Technology Overview
- A. Cancer Statistics and Etiology

## **1. BREAST CANCER**

## **2. LUNG CANCER**

## **3. COLON AND RECTUM CANCER**

## **4. PROSTATE CANCER**

## **5. STOMACH CANCER**

## **6. LEUKEMIA**

## **7. LYMPHOMA**

## **8. ORAL CANCER**

## **9. SKIN CANCER**

## **10. UTERINE CANCER**

## **11. OVARIAN CANCER**

## **12. BLADDER CANCER**

## **B. Major Current And Emerging Cancer Diagnostic Tests**

## **1. INTRODUCTION**

## **2. TUMOR MARKER CLASSIFICATION**

- 3. ACTH**
- 4. ALPHA-FETOPROTEIN (AFP)**
- 5. BETA-2 MICROGLOBULIN**
- 6. CA 15-3/27.29**
- 7. CA 19-9**
- 8. CA-125**
- 9. CALCITONIN**
- 10. CARCINOEMBRYONIC ANTIGEN (CEA)**
- 11. ESTROGEN AND PROGESTERONE RECEPTORS**
- 12. FERRITIN**
- 13. GASTRIN**
- 14. HUMAN CHORIONIC GONADOTROPIN (HCG)**
- 15. INSULIN**
- 16. NSE**
- 17. OCCULT BLOOD**
- 18. PAP SMEAR/HPV**
- 19. PROSTATIC ACID PHOSPHATASE (PAP)**
- 20. PROSTATE-SPECIFIC ANTIGEN (PSA)**
- 21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)**

## 22. T AND B LYMPHOCYTES

## I would like to order

Product name: 2024-2029 Cancer Diagnostic Testing: A Market on the Verge of Explosion--US, Europe, Japan--Supplier Shares and Market Segment Forecasts by Test--Technological Breakthroughs, Emerging Tests, Competitive Analysis

Product link: <https://marketpublishers.com/r/244F78DE9D2DEN.html>

Price: US\$ 14,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/244F78DE9D2DEN.html>